Scribe Therapeutics Inc./$SCTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Scribe Therapeutics Inc.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
- Ticker
- $SCTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 82
- Headquarters
- Alameda, United States
- Website
- www.scribetx.com
SCTX Metrics
BasicAdvanced
$293M
-
-$13.18
-
-
Price and volume
Market cap
$293M
52-week high
$39.60
52-week low
$13.50
Average daily volume
455K
Financial strength
Current ratio
0.573
Quick ratio
0.562
Long term debt to equity
-0.092
Total debt to equity
-0.973
Interest coverage (TTM)
-14.83%
Profitability
EBITDA (TTM)
-27.82
Gross margin (TTM)
-53.28%
Net profit margin (TTM)
-97.00%
Operating margin (TTM)
-92.20%
Effective tax rate (TTM)
1.02%
Revenue per employee (TTM)
$410,000
Management effectiveness
Valuation
Price to revenue (TTM)
1.14
Price to book
-0.23
Price to tangible book (TTM)
-0.23
Price to free cash flow (TTM)
-0.993
Free cash flow yield (TTM)
-100.71%
Free cash flow per share (TTM)
-15.59
Growth
What the Analysts think about SCTX
Analyst ratings (Buy, Hold, Sell) for Scribe Therapeutics Inc. stock.
Analyst projections of the future price of Scribe Therapeutics Inc. stock.
SCTX Financial Performance
Revenues and expenses
SCTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SCTX
Fund name | Fund size | $SCTX weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 1.02% |
ARK Genomic Revolution£ARCG | $123M | 1.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.